BFI Infinity Ltd. Makes New $4.16 Million Investment in AbbVie Inc. $ABBV

Key Points

• BFI Infinity Ltd. acquired 15,882 AbbVie shares worth approximately $4.16 million in the third quarter, making ABBV its 16th-largest holding and 2% of its portfolio. Institutional investors collectively own 70.23% of AbbVie.
• AbbVie is benefiting from positive oncology-trial results, favorable analyst sentiment, and strong growth from newer medicines such as Skyrizi and Rinvoq, helping offset declining Humira revenue. Analysts maintain a consensus “Moderate Buy” rating with a $277.18 price target.
• Shares opened at $285.32, near their 12-month high, while the company declared a quarterly dividend of $1.73, equivalent to a 2.4% annual yield. Key risks include the stock’s elevated valuation and the need for newer products to replace mature blockbuster medicines.

BFI Infinity Ltd. acquired a new stake in AbbVie Inc. (NYSE:ABBV - Free Report) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 15,882 shares of the company's stock, valued at approximately $4,155,000. AbbVie accounts for 2.0% of BFI Infinity Ltd.'s investment portfolio, making the stock its 16th largest position.

Several other large investors have also bought and sold shares of the stock. Granite Islands Private Wealth LLC lifted its holdings in AbbVie by 3.1% during the 3rd quarter. Granite Islands Private Wealth LLC now owns 9,068 shares of the company's stock worth $2,365,000 after buying an additional 272 shares during the period. Patriot Investment Management Group Inc. grew its position in shares of AbbVie by 17.1% in the 3rd quarter. Patriot Investment Management Group Inc. now owns 4,574 shares of the company's stock valued at $1,197,000 after buying an additional 668 shares during the last quarter. ACT Advisors LLC. increased its stake in shares of AbbVie by 6.7% in the third quarter. ACT Advisors LLC. now owns 1,801 shares of the company's stock valued at $471,000 after buying an additional 113 shares during the period. Ellsworth Advisors LLC acquired a new position in shares of AbbVie in the third quarter worth approximately $245,000. Finally, NFSG Corp lifted its stake in shares of AbbVie by 2.6% in the third quarter. NFSG Corp now owns 9,304 shares of the company's stock worth $2,434,000 after acquiring an additional 238 shares during the period. 70.23% of the stock is owned by institutional investors.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Positive Phase 3 cancer-trial results provided the most important company-specific catalyst. AbbVie and Genmab reported that epcoritamab plus R-CHOP significantly reduced the risk of disease progression or death in newly diagnosed diffuse large B-cell lymphoma, strengthening AbbVie’s oncology pipeline and potential long-term growth. What Does AbbVie (ABBV) 51% DLBCL Risk Reduction Mean For Its Oncology Push?
• Positive Sentiment: Analyst and options-market confidence remains favorable. Erste Group Bank issued a positive earnings outlook, Royal Bank of Canada reaffirmed its Outperform rating, and traders purchased an unusually high volume of ABBV call options—signals of bullish expectations ahead of results. Erste Group Bank Issues Positive Outlook for AbbVie Earnings
• Positive Sentiment: Investors continue to view AbbVie as attractively valued for a large-cap pharmaceutical company. Coverage highlights a forward P/E near 16.4, strong year-to-date performance, a durable dividend, and newer medicines growing fast enough to offset declining Humira revenue. AbbVie is Outperforming the Market this Year So Far. Is Its 16.4x Valuation Attractive?
• Positive Sentiment: Sector rotation is helping the stock. Investors have been shifting toward defensive pharmaceutical companies as technology stocks weaken, pushing major drugmakers close to record highs. Big Pharma Stocks Close Near All-Time Highs
• Neutral Sentiment: Investors are now looking ahead to AbbVie’s third-quarter earnings report, scheduled for October 30. The results and updated guidance will test whether recent pipeline momentum and newer-drug growth justify the stock’s rally. AbbVie’s Q3 2026 Earnings: What to Expect
• Negative Sentiment: The primary risk remains the transition away from established blockbusters. AbbVie must prove that newer medicines can sustain earnings as mature products face competition, while its trailing valuation appears elevated despite a more reasonable forward multiple. AbbVie vs. Merck: Which Pharma Stock Offers Better Value?

Insider Buying and Selling at AbbVie

In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of the business's stock in a transaction that occurred on Friday, August 14th. The stock was sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the completion of the sale, the executive vice president directly owned 74,430 shares of the company's stock, valued at approximately $18,607,500. The trade was a 30.53% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 0.06% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several analysts recently commented on the company. BMO Capital Markets upped their target price on AbbVie from $258.00 to $300.00 and gave the company an "outperform" rating in a report on Monday, July 13th. Citigroup raised their price target on shares of AbbVie from $230.00 to $260.00 and gave the stock a "neutral" rating in a report on Wednesday, July 15th. Guggenheim restated a "buy" rating and issued a $288.00 price target on shares of AbbVie in a research report on Friday, October 9th. Bank of America reaffirmed a "buy" rating on shares of AbbVie in a research note on Tuesday, September 8th. Finally, UBS Group upped their price objective on shares of AbbVie from $260.00 to $275.00 and gave the company a "neutral" rating in a research note on Tuesday, October 6th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and six have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, AbbVie has an average rating of "Moderate Buy" and a consensus price target of $277.18.

AbbVie Stock Up 0.7%

AbbVie stock opened at $285.32 on Friday. AbbVie Inc. has a 12-month low of $190.75 and a 12-month high of $291.40. The firm's fifty day moving average is $262.74 and its 200 day moving average is $239.22. The company has a market capitalization of $504.10 billion, a PE ratio of 80.60, a PEG ratio of 1.29 and a beta of 0.24.

AbbVie (NYSE:ABBV - Get Free Report) last posted its quarterly earnings results on Friday, July 31st. The company reported $3.65 EPS for the quarter, topping analysts' consensus estimates of $3.61 by $0.04. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The business had revenue of $16.99 billion during the quarter, compared to analysts' expectations of $16.80 billion. During the same period last year, the company posted $2.97 earnings per share. The business's quarterly revenue was up 10.2% on a year-over-year basis. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Sell-side analysts expect that AbbVie Inc. will post 13.94 EPS for the current fiscal year.

AbbVie Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Investors of record on Thursday, October 15th will be issued a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.4%. The ex-dividend date is Thursday, October 15th. AbbVie's dividend payout ratio is currently 195.48%.

AbbVie Company Profile

AbbVie Inc is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women's health.

The company's products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care.

AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.